PTN Palatin Technologies
- 2.2900
- -0.0600-2.55%
- 2.2999
- +0.0099+0.43%
Palatin Technologies News
Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Palatin Technologies (PTN)
Palatin Spikes as FDA Clears Mid-stage Trial for Weight Loss Therapy
Express News | HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
Palatin Techs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 733.33% HC Wainwright & Co. → $17 Reiterates Buy → Buy 02/28/2024 733.33% HC Wainwright & Co. $
Buy Rating Endorsed for Palatin Technologies Amidst Promising Obesity Treatment Advancements
Express News | FDA Clears Palatin's IND Application For Phase 2 Study Of Bremelanotide Co-Administered With Tirzepatide For Obesity, The Phase 2 Study Is Expected To Start By Mid-2024, With Topline Data Results By The End Of 2024
Express News | Palatin Technologies Inc: Phase 2 Clinical Study Expected to Begin in Mid-Calendar Year 2024
Express News | Palatin Technologies Inc: Topline Data Expected by Calendar Year-End 2024
Express News | Palatin Announces FDA Clearance of Ind Application for the Co-Administration of Bremelanotide With Tirzepatide (GLP-1) for the Treatment of Obesity
10 Micro-Cap Healthcare Stocks Insiders Are Buying
Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested
Buy Rating Affirmed for Palatin Technologies Following Successful Phase 3 Trial of PL9643 for Dry Eye Disease
Palatin Technologies Shares Rise 27% After Positive Trial Results for PL9643
By Chris Wack Palatin Technologies shares were up 27% to $2.24 after the company said it saw positive topline results for its Phase 3 pivotal clinical trial evaluating the safety and efficacy of PL96
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in
Palatin Stock Jumps 16% on Positive Phase 3 Data for Eye Drug
Microstrategy, Apartment Income REIT, Marathon Digital Among Premarket Gainers' Pack
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announce
Palatin Files to Sell 1.92M Shares of Common Stock for Holders
Palatin Technologies(PTN.US) Director Sells US$23,433.72 in Common Stocks
$Palatin Technologies(PTN.US)$ Director DEVEER ROBERT K JR sold 11,700 shares of Common Stocks on Mar 6, 2024 at an average price of $2.0029 for a total value of $23,433.72.Source: Announcement What i
Analysis
Price Target
No Data
